Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M A TemperoH D Kay

Abstract

Thirty patients with advanced measurable pancreatic adenocarcinoma were entered onto a phase II trial with recombinant interferon gamma (Biogen, Cambridge, MA; 10(6) U/m2 daily for 4 days) and monoclonal antibody (Mab) 17-1A (Centocor, Malvern, PA; 150 mg in autologous leukocytes on days 2, 3, and 4 following interferon infusion). The effect of a single interferon gamma treatment on natural and antibody-dependent cellular cytotoxicity (ADCC), Fc receptor occupancy by antibody, and human leukocyte antigen-DR (HLA-DR) expression on monocytes and lymphocytes was also studied. Toxicity was modest and generally limited to grade I to II fever, nausea and vomiting, and hepatotoxicity. Five patients were considered to be nonassessable for response. Of the 25 assessable patients, one objective response (complete remission for a duration of 4 months) was observed. Stable disease for 2 months or greater was noted in nine patients. The median survival for the group was 5 months. Analysis of cytotoxicity data obtained prior to treatment showed reduced natural cytotoxic activity in these patients compared with normal volunteers. A significant improvement in natural cytotoxic activity to normal levels occurred within 24 hours following the in...Continue Reading

Citations

Aug 1, 1996·Cancer·H J Wanebo, M P Vezeridis
May 31, 2002·Expert Opinion on Investigational Drugs·Walter H GünzburgBrian Salmons
Mar 29, 2003·Expert Opinion on Biological Therapy·Lawrence Rosenberg, Mark Lipsett
Feb 13, 1992·The New England Journal of Medicine·A L Warshaw, C Fernández-del Castillo
Jun 4, 2014·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Ramachadran Murali, Thomas Kieber-Emmons
Jan 1, 1991·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·M A TemperoP Pour
Feb 1, 1994·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·Y HagaM A Tempero
Feb 1, 1997·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·H FriessM W Büchler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.